13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • TABITHA

    Acronym: 

    TABITHA

    ACTRN/NCT /ethics: 

    ACTRN12615000232538

    Scientific title: 

    Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2) Positive Australian Patient

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Early detection, diagnosis, prognosis
    Phase Tumour Stream Breast
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Early detection, diagnosis, prognosis
    Phase
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Breast
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    This study will collect data related to the management of women and men with HER2 positive metastatic breast cancer who are treated in routine clinical practice.

    Lay Summary

    Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2) Positive Australian Patient

    Sponsor / Cooperative group

    BioGrid Australia Ltd

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Pamela Cooper pamela.cooper@sa.gov.au 08 8222 6410 Dr Amanda Townsend Not Yet Recruiting